Teva Canada Limited — licence 101810, currently licensed, last inspection rating C (2025-03-04).
No Canadian shortage report is currently matched to this DIN.
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02415666 | GIOTRIF | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Tablet | AFATINIB (AFATINIB DIMALEATE) 20 MG | Marketed |
| 02415674 | GIOTRIF | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Tablet | AFATINIB (AFATINIB DIMALEATE) 30 MG | Marketed |
| 02415682 | GIOTRIF | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Tablet | AFATINIB (AFATINIB DIMALEATE) 40 MG | Marketed |
| 02517035 | MAR-AFATINIB | MARCAN PHARMACEUTICALS INC | Tablet | AFATINIB (AFATINIB DIMALEATE) 40 MG | Marketed |
| 02517019 | MAR-AFATINIB | MARCAN PHARMACEUTICALS INC | Tablet | AFATINIB (AFATINIB DIMALEATE) 20 MG | Marketed |
| 02517027 | MAR-AFATINIB | MARCAN PHARMACEUTICALS INC | Tablet | AFATINIB (AFATINIB DIMALEATE) 30 MG | Marketed |
| 02512777 | SANDOZ AFATINIB | SANDOZ CANADA INCORPORATED | Tablet | AFATINIB (AFATINIB DIMALEATE) 20 MG | Marketed |
| 02512785 | SANDOZ AFATINIB | SANDOZ CANADA INCORPORATED | Tablet | AFATINIB (AFATINIB DIMALEATE) 30 MG | Marketed |
| 02512793 | SANDOZ AFATINIB | SANDOZ CANADA INCORPORATED | Tablet | AFATINIB (AFATINIB DIMALEATE) 40 MG | Marketed |
| 02514591 | TEVA-AFATINIB | TEVA CANADA LIMITED | Tablet | AFATINIB (AFATINIB DIMALEATE) 20 MG | Cancelled Pre Market |
| 02514605 | TEVA-AFATINIB | TEVA CANADA LIMITED | Tablet | AFATINIB (AFATINIB DIMALEATE) 30 MG | Cancelled Pre Market |